Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia
Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) for RN0361-an APOC3 ...
Dual WEE1/YES1 Kinase Inhibitor MRANK-106 Secures FDA IND Clearance, Positioning MindRank in First-in-Class Oncology Pipeline
Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor effects ...
PMGC it has schedules a pre-IND meeting with FDA for EL-22
Northstrive Biosciences announced that it has scheduled a pre-Investigational New Drug, IND, meeting with the U.S. Food and Drug Administration ...
BioSpace12d
Anxious Industry Awaits Makary’s Hearing Amid Disruptions, Layoffs at FDA
The Senate hearing for FDA Commissioner nominee Marty Makary comes after President Trump's NIH pick, Jay Bhattacharya, was ...